D-0087-2023 Class II Ongoing
FDA drug recall D-0087-2023 was initiated by Aurolife Pharma, LLC on Dec 16, 2022 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications The recall status is ongoing. Affected quantity: 7344 bottles.
Recall Details
- Product Type
- Drugs
- Report Date
- Dec 28, 2022
- Initiation Date
- Dec 16, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 7344 bottles
Product Description
Glycopyrrolate Tablets, USP, 1 mg, 100 tablets, Rx Only, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ 08520, NDC 13107-014-01
Reason for Recall
Failed Impurities/Degradation Specifications
Distribution Pattern
Nationwide in the USA and Puerto Rico.
Code Information
Lots: 01422002A1, Expiry: 12/2023; 01421078A3, Expiry: 09/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0087-2023
- openFDA file date
- Nov 3, 2026
- Loaded by RegDataLab
- Nov 4, 2026